-
Recent Posts
- Infants TYLENOL Oral Suspension 1 oz Grape Recall
- Avastin bevacizumab Counterfeit Product
- Wholistic Herbs Inc Koff and Kold Kold Sore Spray Recall
- Victrelis and Ritonavir Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs Drug Safety Communication
- Proton Pump Inhibitors PPIs Drug Safety Communication
Categories
- Anesthesiology
- Avandia
- Cardiology
- Consumer Products
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Infectious Disease
- multiple sclerosis (MS)
- Neurology
- OBGYN
- Oncology
- Pediatrics
- Pharmacy
- Psychiatry
- Rheumatology
- Risk Manager
- Uncategorized
Category Archives: Gastroenterology
Proton Pump Inhibitors PPIs Drug Safety Communication
Proton Pump Inhibitors (PPIs) – Drug Safety Communication: Clostridum Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs AcipHex (rabeprazole sodium) Dexilant (dexlansoprazole) Nexium (esomeprazole magnesium) Omeprazole (omeprazole) Over-the-Counter (OTC) Prevacid (lansoprazole) and OTC Prevacid 24hr Prilosec (omeprazole) and … Continue reading
Posted in Consumer Products, Family Practice, FDA 2012, FDA Notice, FDA Safety Communication, FDA Warning, Gastroenterology
Tagged Aciphex, Dexilant, drug risks, Drug Safety Communication, FDA notice, FDA Safety Communication, FDA warning, Nexium, Omeprazole, Prevacid, Prilosec, Proton Pump Inhibitors PPIs, Proton Pump Inhibitors PPIs Drug Safety Communication, PRotonix, safety label changes, stomach acid reducers, Vimovo, Zegerid
Comments Off
Tysabri (natalizumab) Drug Safety Communication
Tysabri (natalizumab): Drug Safety Communication – New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) AUDIENCE: Neurology, Gastroenterology ISSUE: FDA notified healthcare profesisonals that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal … Continue reading
Tumor Necrosis Factor-alpha (TNFα) Blockers Label Change
Tumor Necrosis Factor-alpha (TNFα) Blockers: Label Change – Boxed Warning Updated for Risk of Infection from Legionella and Listeria including Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab) AUDIENCE: Rheumatology, Gastroenterology, Oncology ISSUE: FDA notified healthcare … Continue reading
Posted in FDA 2011, FDA Label Change, Gastroenterology, Oncology, Rheumatology
Tagged Cimzia (certolizumab pegol), Enbrel (etanercept), Gastroenterology, Humira (adalimumab), Oncology, Remicade (infliximab), Rheumatology, Simponi (golimumab)
Comments Off